Arcturus Therapeutics Holdings (ARCT) Research & Development (2018 - 2026)

Arcturus Therapeutics Holdings has reported Research & Development for 9 years, with the latest figure at $21.5 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 38.31% year-over-year to $21.5 million; the trailing twelve-month figure through Mar 2026 stood at $98.8 million (down 43.99% YoY), and the FY2025 full-year result was $112.2 million, down 42.5% from the prior year.
• Research & Development for Q1 2026 stood at $21.5 million, down from $24.5 million in the prior quarter.
• The five-year high for Research & Development was $58.7 million in Q2 2024, with the low at $21.5 million in Q1 2026.
• Historically, Research & Development has averaged $39.3 million across 5 years, with a median of $38.2 million in 2022.
• Annual changes were most pronounced in 2023 — Research & Development surged 37.91% — and 2025, when it plunged 49.58%.
• Arcturus Therapeutics Holdings' Research & Development stood at $27.0 million in 2022, then jumped by 35.73% to $36.6 million in 2023, then increased by 19.55% to $43.8 million in 2024, then plunged by 44.09% to $24.5 million in 2025, then retreated by 12.05% to $21.5 million in 2026.
• The last three Research & Development figures came in at $21.5 million (Q1 2026), $24.5 million (Q4 2025), and $23.3 million (Q3 2025), per Business Quant data.